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Summary
QUESTIONS UNDER STUDY: The aim of this retrospect-
ive analysis was to evaluate the safety and efficacy of local
hyperthermia (HT) and reirradiation (ReRT) in the man-
agement of preirradiated locoregional recurrent breast can-
cers at Kantonsspital Aarau, Switzerland.
METHODS: Twenty-four previously irradiated patients
who had developed locoregional recurrences in the chest
wall or breast, with or without regional lymph node in-
volvement, were reirradiated to a mean dose of 36.8 Gy
(range 20–50 Gy) delivered at a mean dose per fraction of
2.33 Gy (range 1.8–4.0 Gy). All patients received local HT
at 41 to 43 °C, once or twice a week prior to radiotherapy.
Online thermometry was carried out during the hyperther-
mia sessions.
RESULTS: An overall objective response rate of 91.7%
(22/24) with a complete response in 66.7% (16/24) of pa-
tients and partial response in 25% (6/24) of patients was
observed. Post-thermoradiotherapy follow-up ranged from
1 to 38 months (median 10 months). The 3-year actuarial
local control rate was 59.7%. More patients who attained
complete response had sustained locoregional control until
their death or last follow-up when compared with those
who were partial or non-responders (median local disease-
free survival for complete responders not reached; for par-
tial and non-responders 4 months; p <0.001). Post-retreat-
ment median overall survival for all 24 patients was 10
months. Grade III/IV acute toxicity was seen in only one
patient and no patient had any significant late morbidity.
CONCLUSIONS: ReRT and HT is an effective and a safe
modality to treat locoregional recurrences in previously ir-
radiated breast cancers. The approach can lead to sustain-
able long-term palliation with minimal morbidity.
Key words: hyperthermia; reirradiation; recurrent; breast
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Introduction
Around one-third of breast cancer patients develop locore-
gional recurrences during their follow-up and more than
80% of the recurrences are known to occur within the first
5-years of their primary treatment [1, 2]. Of these recur-
rences, 85% are located in the original tumour bed with
15% at other sites in the breast or even a de novo tumour
[3]. Various therapeutic approaches have been advocated to
treat these locoregional recurrences. These include surgery,
radiation therapy (RT) and chemotherapy either alone or in
combination [1, 4–8].
Mastectomy, considered a gold standard for treating recur-
rences after breast conservation, may result in a second
local recurrence in 2% to 31% of patients [9]. For those
who had undergone mastectomy as part of their initial treat-
ment, repeat surgery for recurrences provides local control
in only one-third of the patients [10]. In preirradiated pa-
tients, reirradiation (ReRT) increased the risk of acute and
late toxicity owing to an increase in cumulative radiation
dose. Wahl et al., [8] in a multi-institutional review of
ReRT in recurrent breast cancer, reported a complete re-
sponse rate of 39% even with a median cumulative dose
of 106 Gy (range 74.4–137.5 Gy). A Cochrane review did
not find conclusive evidence for use of chemotherapy in the
management of these locoregional recurrences [6]. Thus,
management of locoregional recurrences in breast cancers
after primary treatment is indeed a therapeutic challenge.
Hyperthermia (HT), at 41 to 43 °C, is a known radiosensit-
iser with minimal morbidity and enhances the efficacy of
radiation through its unique thermoradiobiological proper-
ties [11, 12]. It complements the radiation-induced tumour-
icidal effects through hypoxic cell sensitisation and reduces
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repair of radiation-induced DNA damage [12, 13]. This
provides the basis for using HT with moderate doses of ra-
diation to treat chest wall recurrences, which has been re-
ported to have reasonable success and minimal morbidity
[14–27].
In the literature, the approaches to treatment of these re-
current breast cancers with hyperthermia have been vari-
able [14–27]. Those that were operable were operated upon
and then treated with ReRT and HT. Patients with no pre-
vious RT have been treated with higher radiation doses.
However, those lesions considered inoperable and which
had also been exposed to previous RT pose a greater
theraputic challenge. Herein, we share our experience of
treating inoperable locoregional recurrences with local HT
and ReRT in preirradiated breast cancers.
Patients and methods
Patient population
Between 2006 and 2013, a total of 46 breast cancer patients
with locoregional recurrences were referred to our institute
for further management. Of these, 24 had been previously
irradiated and were now considered for local HT and ReRT.
The initial diagnosis and treatment of these patients were
carried out between 1986 and 2011. The median interval
to recurrence after initial treatment was 6 years (range
2–22 years) (table 1). All patients had received RT, with
a median dose of 54 Gy (range 30‒70 Gy). They received
multimodality treatment including surgery, chemotherapy
and hormonal intervention according to their initial disease
stage and the treatment policies of the referring hospitals.
The primary indication for HT and ReRT was inoperable
Figure 1
Steps involved in the hyperthermia treatment delivery for a patient
with locoregional recurrent breast cancers. (a) Patient with the
chest wall recurrence following previous radiotherapy. (b)
Placement of multiple thermometry sensors all around the tumour
in the area to be treated with hyperthermia. (c) Superficial
hyperthermia treatment unit (BSD 500, 915 MHz). (d) Temperature
profiles in a phantom showing the heating patterns with 915 MHz
radiofrequency applicators. A water bolus has been sandwiched
between the applicators and the phantoms to simulate the
treatment conditions. A temperature ranging from 40–43 °C could
be achieved to a depth of 3 cm. (e) and (f) Actual treatment setup
with online recording of the temperature profiles. (g) and (h)
Tumour regression observed at 3 weeks and at completion of
treatment with minimal skin morbidity. The patient went on to
achieve a complete response at 6 weeks of completion of
reirradiation and hyperthermia.
locoregional recurrent disease following previous irradi-
ation.
Two-thirds of the patients (n = 16) had isolated chest wall
recurrence and four had isolated recurrences in the regional
nodes. Two patients had recurrences in the chest wall and
regional nodes. In addition, two patients had recurrence
after breast conservation treatment: one only in the ipsi-
lateral breast, the other in both the breast and regional
lymph nodes. The recurrences varied from isolated or mul-
tiple ulcerative or nodular lesions to diffuse lesions in the
chest wall or breast, with or without regional lymphadeno-
pathy. No surgical intervention was carried out for the re-
currences, either because they were deemed inoperable or
because surgery was perceived to add no appreciable bene-
fit . None of the patients received any chemotherapy during
the ReRT and HT treatments.
Fourteen of these 24 patients (58.3%) also had distant
metastasis at the time of referral for treatment of locore-
gional recurrent disease. The distant metastases occurred
mainly as isolated or multiple lesions in bones, lungs, liver
and/or brain for which the patients were receiving salvage
chemotherapy / hormonal manipulation. Salvage chemo-
therapy was withheld during the time of ReRT and HT, but
patients were allowed to continue hormonal therapies.
Reirradiation
The ReRT dose and fractionation were individualised on
the basis of the site of recurrence, previous RT doses re-
ceived at the recurrence site, time of previous RT, present
disease status and the expected survival. Thus, the ReRT
dose ranged from 20 to 50 Gy (median 39 Gy) delivered at
a dose per fraction of 1.8 to 4 Gy (median 2.07 Gy) in 5 to
25 fractions (median 15.5 fractions) (table 2). Radiotherapy
treatment planning was carried out for all patients and, de-
pending on the tumour site and size, patients were treated
either with a 6 MV photon beam or with electrons with en-
ergy adapted to the tumour thickness and the desired treat-
ment depth. The summated median RT dose of the primary
RT and ReRT was 94.5 Gy (range 55‒114 Gy).
Local hyperthermia
Local hyperthermia was administered with the superficial
hyperthermia unit, BSD-500 (BSD Medical Corporation,
USA), capable of generating microwaves at 915 MHz. The
system has three surface applicators with 3, 8 or 24 spiral
antennas that cover a diameter of 9 cm, 12 cm or an area of
24 x 20 cm, respectively. Depending on the size and extent
of the recurrent lesions, the applicator that would well en-
compass all the recurrent lesions was selected and placed
directly over the treatment volume. At 915 MHz, the de-
sired temperature of 41 to 43 ˚C could be attained within
the intervening tissues up to a maximum depth of 3 cm.
Thus, all patients considered for HT had lesions not extend-
ing beyond a depth of 3 cm from the skin surface. This was
ensured from the computed tomography (CT) / positron
emission tomography-CT (PET-CT) or magnetic resonance
imaging (MRI) scans undertaken before the patients were
accepted for the HT treatment.
All patients were quite comfortable during the treatment
and did not require any analgesia. The HT applicators
provide an inbuilt water bolus with recirculating water for
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surface cooling. This ensures contact between the applicat-
or and the patient and maintains a controlled temperature
of the skin surface. Well-controlled coupling of the mi-
crowave field from applicator into tissue is necessary for
uniform heating, and the skin cooling helps prevent over-
heating of the skin surface, which may cause thermal
blisters or, in rare cases, deeper burns in subcutaneous tis-
sue.
For online temperature monitoring, four temperature
sensors were placed in and around the lesions on the
overlying skin and once a temperature of 41 to 43 °C was
attained, it was maintained for 60 minutes during the heat-
ing session. Patients were treated with HT once a week (7
patients) or twice a week (17 patients), 30 minutes before
RT. Thus, for patients on 5 RT fractions a week, HT was
administered once or twice a week with RT while on the re-
maining days, the patients were treated with RT alone. The
number of HT sessions ranged from 2 to 11 (median 7 ses-
sions) (table 2). The steps of HT treatment delivery are de-
picted in figure 1.
Evaluation of local response and associated morbidity
All patients were closely monitored during treatment for
any therapy-related acute or late morbidity as in the Com-
mon Terminology Criteria for Adverse Events (CTCAE)
[28, 29]. Skin and subcutaneous tissue disorders were the
primary toxicities evaluated according to the CTCAE
guidelines. These included – bullous dermatitis, dryness
of skin, erythroderma, skin pigmentation, skin induration,
skin ulceration and telangiectasia. Late toxicity was scored
only in patients who had a follow-up of more than 90 days
from the date of completion of ReRT and HT.
Tumour responses were evaluated at 4 weeks after com-
pletion of treatment according to the Response Evaluation
Criteria in Solid Tumours (RECIST) [30, 31]. In accord-
ance with the RECIST guidelines, measurable lesions were
measured either clinically (on each visit) or on periodic
imaging (CT/MRI/PET), and nonmeasurable lesions (dif-
fuse or nodular skin infiltration with each lesion less than
10 mm) were evaluated clinically. A complete response
was defined as disappearance of all target lesions at 4
weeks from completion of ReRT and HT.
Statistical considerations
All statistical calculations were performed using IBM
SPSS software package, version 21.0. For survival ana-
lysis, the status of all patients at last follow-up was con-
sidered. Actuarial local control represented the status of the
local recurrence at the time of last follow-up or death. All
patients with a complete locoregional response at their last
follow-up or death were considered as “censored”, where-
as those with partial or no response were considered as
“events.” For computation of overall survival, all patients
surviving were considered as “censored,” and those dead
from any cause or lost to follow-up were considered as
“events.” Kaplan-Meier estimates were used to test the dif-
ferences in survival outcomes between complete respon-
ders and non-complete responders [32]. A logistic regres-
sion was carried out to identify any predictive variable for
complete response at the end of ReRT and HT. Various pa-
tient and treatment related factors (age, tumour grade, hor-
mone receptor [ERPR] status, HER2 status, prior treatment
offered, ReRT dose [in terms of biological equivalent dose
with tumour α/β = 10], number of HT sessions per week,
total number of HT sessions received, time gap between
the previous RT and the present ReRT) were entered into
the logistic regression using forward (conditional) method.
The multivariate analysis for actuarial local control was
performed using Cox’s proportional hazard model [33].
Table 1: Patient characteristics at the time of referral for reirradiation and hyperthermia.
Parameter Value
Age 38–88 years (66.0 ± 15.1)*
Interval between 1st treatment and retreatment 2–22 years (7.6 ± 5.7)*
Site of recurrence
Chest wall 16 (66.6%)
Regional lymph nodes 4 (16.7%)
Chest wall and regional lymph nodes 2 (8.3%)
Breast 1 (4.2%)
Breast and regional lymph nodes 1 (4.2%)
Initial group stage#
Stage I 6 (25%)
Stage II 3 (12.5%)
Stage III 13 (54.2%)
Stage IV 2 (8.3%)
Previous treatment received (alone or in combination)
Radiotherapy 24 (100%)
Surgery 23 (95.8%)
Chemotherapy 20 (83.3%)
Hormonal therapy 15 (62.5%)
Previous radiotherapy dose 30–70 Gy (53.7 ± 10.5)*
* Mean ± standard deviation
# Stage of the disease at the time of initial presentation
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Results
Post-HT and -ReRT locoregional response and survival
After local thermoradiotherapy, 22 of the 24 patients
(91.7%) demonstrated a clinical response to ReRT and HT.
Sixteen patients (66.7%) had a complete regression and 6
(25%) had partial regression (fig. 2). During the median
follow-up period of 10 months (range 1‒36 months), all pa-
tients with a complete response continued to maintain their
complete remission until their last follow-up or death. One
patient who had a partial response at 4 weeks from treat-
ment completion went on to have a complete response by 8
weeks. Thus, 17 of the 24 patients who at the time of their
last follow up had complete locoregional control were con-
sidered as “censored” for the computation of their actuar-
ial local control by means of Kaplan-Meier estimates. The
actuarial local control rates at 2 and 3 years was estimated
to be 76.8% and 59.7%, respectively. There was a signific-
ant difference between the complete responders and others
(p <0.001, fig. 3). Median overall survival for all patients
was 12 months, 23 months for complete responders and
Figure 2
(a) Patient with isolated chest wall recurrence. (b) Complete
locoregional response was achieved and sustained after
reirradiation and hyperthermia at 2 years after the treatment.
Figure 3
(a) Actuarial local control for all patients of recurrent breast cancers
following reirradiation and hyperthermia. (b) Actuarial local control
in complete responders (CRs) vs non-CRs (p <0.001).
LDFS = local disease-free survival
4 months for incomplete responders (p = not significant).
Seven patients were alive and 13 had died from disease
progression. The follow-up status of four patients could
not be obtained and hence these patients were considered
as lost to follow-up. They were considered as “event” for
computation of overall survival, as because of their ad-
vanced disease status, it may be more realistic to consider
them as events.
No significant predictive factor could be detected in mul-
tivariate logistic regression for complete responders. In
Cox’s proportional hazard model, the only variable that
was included in the regression model was response at end
of ReRT and HT (exp (β) = 0.004; 95% confidence interval
[CI] 0.000‒7.227, p = 0.150). The same factor was also sig-
nificant in univariate analysis as evident from the Kaplan-
Meier survival estimates (p <0.001).
Acute and late morbidity
All patients tolerated the treatment, and were able to com-
plete the assigned HT treatment sessions and ReRT without
any appreciable problems. They had good compliance with
ReRT and HT. Acute skin grade I and II toxicity was ex-
perienced by 23 of the 24 patients, but only 1 (4.1%) pa-
tient had a grade III acute skin morbidity. The lesion healed
within 4 weeks with conservative treatment. Late toxicity
at more than 90 days after completion of ReRT and HT was
evaluable in 22 patients and none had any significant late
morbidity attributable to local HT and ReRT.
Discussion
Locoregional recurrences in previously irradiated breast
cancers pose a delicate problem of delivering adequate ra-
diation doses for tumour control and at the same time min-
imising the acute and late toxicity that could result from the
cumulative dose of primary RT and ReRT. Patients with lo-
coregional recurrences are known to survive after control
of their local disease and hence development of such le-
sions may not always indicate a fatal outcome and signal
institution of purely palliative measures. Willner et al. [34]
in a study of 145 patients with locoregional recurrence have
reported that 36% of the patients were alive and free of dis-
tant disease at 10 years. Hence, it may be desirable to treat
these local recurrences effectively to achieve a long-term
local disease control and to expect the patient to have a
reasonable quality of life. Treatment approaches thus need
to be tailor-made not only to be effective, but also to have
the least acute and late morbidities. Increasing the ReRT
Table 2: Retreatment offered with reirradiation and local hyperthermia.
Treatment offered Values
Reirradiation
ReRT dose (Gy) 20–50 (36.8 ± 8.5)*
No. of fractions 5–25 (17.2 ± 5.7)*
Dose per fractions (Gy/fr.) 1.8–4.0 (2.3 ± 0.5)*
Hyperthermia
Total no. of sessions 2–11 (7.3 ± 2.3)*
Average temperature (°C) 41–43.5 (40.6 ± 0.9)*
Total radiotherapy dose (Previous RT + ReRT) (Gy) 55–114 (90.6 ± 14.1)*
ReRT = reirradiation; RT = radiotherapy
* Mean ± standard deviation
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doses or using a higher dose per fraction could increase the
risks of acute and long-term late toxicities and thereby be
counterproductive.
Hyperthermia with ReRT is one of the modalities that have
been tried to treat these lesions. A common approach has
been the use of moderate doses of ReRT and HT and
this has given reasonable complete response ratess varying
from 33.3% to 67% with a range of ReRT dose schedules
and HT treatment parameters [8, 14–17, 19–23, 25–27].
However, the acute and late toxicities are a matter of con-
cern with ReRT, especially for previously irradiated pa-
tients. The choice of the optimal thermal and ReRT treat-
ment parameters thus requires special consideration as a
higher temperature and a higher ReRT dose could result in
increased morbidity.
Locoregional recurrence in the breast has also been treated
with RT alone [1]. However, addition of HT with ReRT
improves the outcomes as a result of the thermoradiobio-
logical advantages of thermoradiotherapy as evident from
randomised trials comparing ReRT and HT with RT alone.
The International Collaborative Hyperthermia Group re-
ported a complete response rate of 57% with thermoradio-
therapy versus 31% with ReRT alone (odds ratio 4.7; CI
2.4–9.5) in previously irradiated patients [14]. In a study
from Duke’s University, the complete response was repor-
ted to be 66.1% with ReRT and HT versus 42.3% with
ReRT alone (p = 0.02) [18]. In contrast, the randomised
trial by the Radiation Therapy Oncology Group (RTOG),
protocol 8104, reported a nonsignificant difference in com-
plete response of 33.3% with ReRT and HT versus 30.7%
with ReRT alone [26]. This has been ascribed to the subop-
timal heating quality and thermometry during HT sessions
[35, 36].
One of the other approaches that have also been success-
fully advocated is surgical excision of the recurrences fol-
lowed by ReRT and HT. This has been shown to produce
sustainable local control [37, 38]. However, this is possible
only in patients with operable isolated and gross recurrent
lesions where a complete excision, preferably with negat-
ive margins, could be effectively controlled by moderate
doses of ReRT with HT.
Chemotherapy has also been tried to treat recurrent breast
cancer lesions. The Cochrane review failed to document
conclusive evidence of benefit with chemotherapy alone
[6]. A pilot study of weekly paclitaxel and HT in seven pa-
tients reported a complete response in four with no signi-
ficant toxicity [39]. In a phase I/II trial, liposomal doxor-
ubicin with ReRT and HT produced a complete response
in 3 out of the 15 patients [40]. A triple modality approach
with chemotherapy (epirubicin and ifosphamide), HT and
ReRT has also been reported by Feyerabend et al. [41].
They reported a complete response rate of 44%, especially
in noninflammatory recurrent breast cancers. Borenstein et
al. [42] observed a complete response of 53% with ther-
mochemoradiotherapy using cisplatin with or without bleo-
mycin or etoposide in recurrent breast cancers. However,
they observed a higher toxicity with this approach and con-
cluded that in preirradiated patients, the triple combination
appeared to be more toxic than combined ReRT and HT.
It is desirable to tailor the radiation dose and fractionation
schemes, and take into account the previous RT doses to
the site of reirradiation, the time interval between the
primary and the retreatment, present disease status, expec-
ted survival and also other comorbid conditions to achieve
an optimal outcome. As evident from our data, a range of
ReRT dose schedules have been used to adapt to individu-
al patient profiles. A satisfactory sustainable local control
was achieved in two-thirds of our patients with minimal
acute morbidity (Grade III acute toxicity: 1/24). Moreover,
the complete response to ReRT and HT was maintained un-
til the time of death or last follow-up. Similar observations
have also been reported by Wahl et al. [8]. None of our
patients had any long-term toxicity during the median fol-
low up of 10 months (range 1–38 months). Moreover, in
patients with partial responses, the local disease was reas-
onably controlled, which provided a reasonable palliation
(fig. 3). Since 58.3% of the patients (14/24) already had
metastatic disease at the time of recurrence, local treatment
with ReRT and HT should not be expected to improve the
overall survival, but at least to provide effective palliation
without any superimposed morbidity. Addition of HT to
ReRT has been, therefore, an effective therapeutic modal-
ity to treat postirradiated locoregional recurrent breast can-
cers. Even with a moderate dose of radiation, thermoradio-
therapy produces a sustained complete regression in nearly
two-thirds of the patients without any significant additional
morbidity. This further demonstrates that HT is one of the
most potent radiosensitizers [12].
Thus, a delicate balance of the various retreatment para-
meters – namely ReRT dose schedules and HT treatment
variables ‒ needs to be tailored to the patient’s disease
status to achieve the optimal outcome for these patients.
ReRT with local HT can certainly be a viable and effective
treatment strategy for treating locoregional recurrent breast
cancers. A multicentre well designed clinical trial with ad-
equate sample size to address these issues is certainly war-
ranted.
To date, only a few centres have hyperthermia treatment fa-
cilities. This could rapidly change as encouraging results
of HT in various tumour sites are being reported [43].
Moreover, with the recent developments in hardware and
software, HT could fast emerge as an effective and a safer
addendum to the existing treatment modalities, not only for
recurrent breast tumours but also for tumours in other sites.
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Figures (large format)
Figure 1
Steps involved in the hyperthermia treatment delivery for a patient with locoregional recurrent breast cancers. (a) Patient with the chest wall
recurrence following previous radiotherapy. (b) Placement of multiple thermometry sensors all around the tumour in the area to be treated with
hyperthermia. (c) Superficial hyperthermia treatment unit (BSD 500, 915 MHz). (d) Temperature profiles in a phantom showing the heating
patterns with 915 MHz radiofrequency applicators. A water bolus has been sandwiched between the applicators and the phantoms to simulate
the treatment conditions. A temperature ranging from 40–43 °C could be achieved to a depth of 3 cm. (e) and (f) Actual treatment setup with
online recording of the temperature profiles. (g) and (h) Tumour regression observed at 3 weeks and at completion of treatment with minimal
skin morbidity. The patient went on to achieve a complete response at 6 weeks of completion of reirradiation and hyperthermia.
Figure 2
(a) Patient with isolated chest wall recurrence. (b) Complete locoregional response was achieved and sustained after reirradiation and
hyperthermia at 2 years after the treatment.
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Figure 3
(a) Actuarial local control for all patients of recurrent breast cancers following reirradiation and hyperthermia. (b) Actuarial local control in
complete responders (CRs) vs non-CRs (p <0.001).
LDFS = local disease-free survival
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